Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease

Gerontology

Volumn 45, Issue SUPPL. 1, 1999, Pages 15-22

  Levy, M L ^a,b   Cummings, Jeffrey L ^a,c   Kahn Rose, R ^a  

^a Dept Psychiat Biobehavioral Sci ^*  (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Neuropsychiatric symptoms

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; METRIFONATE; RIVASTIGMINE; TACRINE; XANOMELINE;

AGITATION; ALZHEIMER DISEASE; ANXIETY; APATHY; BRADYCARDIA; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; CONFERENCE PAPER; DETERIORATION; DIARRHEA; DRUG TOLERANCE; INSTITUTIONALIZATION; LANGUAGE; MEMORY; MENTAL DISEASE; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; SWEATING; VOMITING;

ACETYLCHOLINE; AGED; ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; BRAIN; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 0032928421     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052760     Document Type: Conference Paper

References (63)

1. Mega M, Cummings JL, Fiorello T, Gornbcin J: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.
2. O'Donnell BF, Drachman DA. Barnes HJ, Peterson KE, Swearer JM, Lew RA: Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992;5:45-52.
3. Borson S, Raskind MA: Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 1997; 48(suppl 6):S17-S24.
4. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Litvan I, Craig AH, Paulsen JS: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314-319.
5. Rovner BW, Broadhead J, Spencer M, Carson K, Folstein MF: Depression and Alzheimer's disease. Am J Psychiatry 1989;146:350-353.
6. Weiner MF, Edland SD, Luszczynska H: Prevalence and incidence of major depression in Alzheimer's disease. Am J Psychiatry 1994; 151:1006-1009.
7. Swearer JM, Drachman DA, O'Donnell BF, Mitchell AL: Troublesome and disruptive behaviors in dementia. J Am Geriatr Soc 1988; 36:784-790.
8. Colenda CC III: Agitation: A conceptual overview; in Lawlor BA (ed): Behavioral Complications in Alzheimer's Disease. Washington, American Psychiatric Press, 1995, pp 3-17.
9. Rubin EH, Drevets WC, Burke WJ: The nature of psychotic symptoms in senile dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1988;1:16-20.
10. Reisberg B, Fransscn E, Sclan SG, Kluger A, Ferris SH: Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease. Bull Clin Neurosci 1989;54:95-112.
11. Ryden MB: Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord 1988;2:342-355.
12. Dura JR, Stukenberg KW, Kiecolt-Glaser JK: Anxiety and depressive disorders in adult children caring for demented parents. Psychol Aging 1991;6:467-473.
13. Pillemer K, Suitor JJ: Violence and violent feelings: What causes them among family care-givers? J Gerontol 1992;47:S165-S172.
14. Rovner BW, Kafonek S, Filipp L, Lucas MJ, Folstein MF: Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986;143:1446-1449.
15. Morriss RK, Rovner BW, Folstein MF, German PS: Delusions in newly admitted residents of nursing homes. Am J Psychiatry 1990;147: 299-302.
16. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-1051.
17. Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF: Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry 1991;148:1159-1163.
18. Martinson IM, Muwaswes M, Gilliss CL, Doyle GC, Zimmerman S: The frequency and troublesomeness of symptoms associated with Alzheimer's disease. J Community Health Nurs 1995;12:47-57.
19. Ferris SH, Steinberg G, Shulman E, Kahn R, Reisberg B: Institutionalization of Alzheimer's disease patients: Reducing precipitating factors through family counseling. Home Health Care Serv Q 1987;8:23-51.
20. Cohen-Mansfield J, Billig N: Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc 1986;34:711-721.
21. Rovner BW, German PS, Broadhead J, Morriss RK, Brant LJ, Blaustein J, Folstein MF: The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int Psychogeriatr 1990;2:13-24.
22. Snow C: Medicare HMOs develop plan for future of Alzheimer's programming. Modem Healthcare 1996; Sept 23:67-70.
23. Nieuwenhuys R: Chemoarchitecture of the Brain. New York, Springer. 1985.
24. Jean JC, Schwarz RD: Development of muscarinic agonists for the symptomatic treatment of Alzheimer's disease: in Brioni JD, Decker MW (eds): Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. New York, Wiley-Liss, 1997, pp 409-432.
25. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
26. Coyle JT, Price DL, DeLong MR: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
27. Davies P: Studies on the neurochemistry of central cholinergic systems in Alzheimer's disease; in Katzman R, Terry RD, Bick KL (eds): Alzheimer's Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, pp 453-459.
28. Procter AW, Lowe SL, Palmer AM, Francis PT, Esiri MM, Straimann GC, Najlerahim A, Patel AJ, Hunt A, Bowen DM: Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 1988;84:125-140.
29. Cummings JL, Benson DF: Dementia: A Clinical Approach, ed 2. Boston, Butterworth-Heinemann, 1992.
30. Janowsky DS, Risch SC, Gillin JC: Adrenergiccholinergic balance and the treatment of affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:297-307.
31. Cummings JL, Kaufer DI: Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996;47:876-883.
32. Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993;33:536-541.
33. Craig AH, Cummings JL, Fairbanks L, Itti L, Miller BL, Li J, Mena I: Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-1120.
34. Cummings JL, Back C: The cholinergic hypothesis of neuropsychiatrie symptoms in Alzheimer's disease. Am J Geriatr Soc 1998; 6(suppl 1):64-78.
35. Starkstein SE, Vazquez S, Petracca G, Sabe L, Migliorelli R, Teson A, Leiguarda R: A SPECT study of delusions in Alzheimer's disease. Neurology 1994;44:2055-2059.
36. Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R: SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry 1995; 152:1470-1475.
37. Mentis MJ, Weinstein EA, Horwitz B, McIntosh AR, Pietrini P, Alexander GE, Furey M, Murphy DG: Abnormal brain glucose metabolism in the delusional misidentification syndromes: A positron emission tomography study in Alzheimer disease. Biol Psychiatry 1995;38: 438-449.
38. Ponton MO, Darcourt J, Miller BL, Cummings JL, Schumann SE, Mena I: Psychometric and SPECT studies in Alzheimer's disease with and without delusions. Neuropsychiatry Neuropsychol Behav Neurol 1995;8:264-270.
39. Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA: The relationship between psychiatric symptoms and regional cortical metabolism in Azheimer's disease. J Neuropsychiatry Clin Neurosci 1995;7:476-484.
40. Granacher RP, Baldessarini RJ: Physostigmine: Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch Gen Psychiatry 1975;32:375-380.
41. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM: Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
42. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA III, Murphy DL: Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 1987;44:418-426.
43. Gorman DG, Read S, Cummings JL: Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-234.
44. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
45. Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB: Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 1987; 144:468-471.
46. Whitehouse PJ: Intraventricular bethanechol in Alzheimer's disease: A continuing controversy (editorial). Neurology 1988;38:307-308.
47. Zubenko GS, Moossy J, Kopp U: Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990;47:209-214.
48. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
49. Gracon SI: Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. Acta Neurol Scand Suppl 1996;165:114-122.
50. Rogers SL, Farlow MR, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
51. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031.
52. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension trial. Eur Neuropsychopharmacol 1998;8: 67-75.
53. Lahiri DK, Farlow MR: Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci 1996;7:41-49.
54. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S: Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology 1996;47:166-177.
55. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
56. Smucker WD: Maximizing function in Alzheimer's disease: What role for tacrine? Am Fam Physician 1996;54:645-652.
57. Rogers SL, Friedhoff LT: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
58. Giacobini E: The second generation of cholinesterase inhibitors: Pharmacological aspects: in Becker R, Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston, Birkhäuser, 1991, pp 247-262.
59. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S: Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:124-131.
60. Cummings L, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, and the Metrifonate Study Group: Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221.
61. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
62. Kaufer DI, Catt K, Pollock BG, Lopez OM, DeKosky ST: Donepezil in Alzheimer's disease: Relative cognitive and neuropsychiatrie responses and impact on caregiver distress. Neurology 1988;50(suppl 4):A89(P02.013).
63. Warpman U, Alafuzoff I, Nordberg A: Coupling of muscarinic receptors to GTP proteins in postmortem human brain - Alterations in Alzheimer's disease. Neurosci Lett 1993;150: 39-43.